SE453153B - Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin - Google Patents
Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillinInfo
- Publication number
- SE453153B SE453153B SE8200591A SE8200591A SE453153B SE 453153 B SE453153 B SE 453153B SE 8200591 A SE8200591 A SE 8200591A SE 8200591 A SE8200591 A SE 8200591A SE 453153 B SE453153 B SE 453153B
- Authority
- SE
- Sweden
- Prior art keywords
- concentration
- lyophilized
- piperacillin
- dosage unit
- sodium piperacillin
- Prior art date
Links
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000003708 ampul Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000012467 final product Substances 0.000 description 11
- 150000002960 penicillins Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 229960002292 piperacillin Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- IVBHGBMCVLDMKU-UHFFFAOYSA-N 6-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1C(=O)N(CC)CCN1C(=O)NC(C=1C=CC=CC=1)C(=O)NC1C(=O)N2C(C(O)=O)C(C)(C)SC21 IVBHGBMCVLDMKU-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24758681A | 1981-03-26 | 1981-03-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8200591L SE8200591L (sv) | 1982-09-27 |
| SE453153B true SE453153B (sv) | 1988-01-18 |
Family
ID=22935482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8200591A SE453153B (sv) | 1981-03-26 | 1982-02-02 | Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin |
Country Status (23)
| Country | Link |
|---|---|
| JP (1) | JPS57159708A (cs) |
| AT (1) | AT395533B (cs) |
| AU (1) | AU549784B2 (cs) |
| BE (1) | BE892541A (cs) |
| CA (1) | CA1209477A (cs) |
| CH (1) | CH652306A5 (cs) |
| DE (2) | DE19375106I2 (cs) |
| DK (1) | DK157976C (cs) |
| ES (1) | ES8302455A1 (cs) |
| FR (1) | FR2502624B1 (cs) |
| GB (1) | GB2095551B (cs) |
| GR (1) | GR78386B (cs) |
| HK (1) | HK39189A (cs) |
| HU (1) | HU186489B (cs) |
| IE (1) | IE52936B1 (cs) |
| IL (1) | IL64924A (cs) |
| IT (1) | IT1147916B (cs) |
| LU (1) | LU84031A1 (cs) |
| NL (1) | NL192664C (cs) |
| NZ (1) | NZ199632A (cs) |
| PL (1) | PL130564B1 (cs) |
| SE (1) | SE453153B (cs) |
| ZA (1) | ZA82605B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207661B1 (en) | 1999-02-22 | 2001-03-27 | Baxter International Inc. | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
| AU2004285448C1 (en) | 2003-10-23 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
| ITMI20051630A1 (it) * | 2005-09-02 | 2007-03-03 | Acs Dobfar Spa | Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi |
| US9457026B2 (en) | 2007-07-31 | 2016-10-04 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
| CN114200057A (zh) * | 2021-12-14 | 2022-03-18 | 坛墨质检科技股份有限公司 | 一种可替代标准溶液的抗生素类药物固体混合标准物质的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2608507A (en) * | 1949-08-20 | 1952-08-26 | Sharp & Dohme Inc | Dialkyl sulfamyl benzoic acids |
| CH546783A (de) * | 1971-03-11 | 1974-03-15 | Hoffmann La Roche | Verfahren zur herstellung von penicilloinsaeurederivate. |
| JPS5817728B2 (ja) * | 1973-11-20 | 1983-04-09 | 山之内製薬株式会社 | アンピシリンナトリウムエン ノ セイホウ |
| IL47168A (en) * | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
| JPS52143221A (en) * | 1976-05-22 | 1977-11-29 | Yamanouchi Pharmaceut Co Ltd | Novel preparations for rectal administration |
| DE2623835C2 (de) * | 1976-05-28 | 1978-03-02 | C.H. Boehringer Sohn, 6507 Ingelheim | Verfahren zur Herstellung von Natriumampicillin |
| JPS542337A (en) * | 1977-06-08 | 1979-01-09 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
| FR2403078A1 (fr) * | 1977-09-19 | 1979-04-13 | Lafon Labor | Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic |
| JPS54147917A (en) * | 1978-05-08 | 1979-11-19 | Sumitomo Chem Co Ltd | Ferrze-drying method |
| PT70225A (en) * | 1978-10-03 | 1979-10-01 | Gist Brocades Nv | Process for the preparation of sodium amoxicillin preparations |
| DE2925009A1 (de) * | 1979-06-21 | 1981-01-08 | Basf Ag | Zubereitung fuer substanzen, verfahren zu deren herstellung und deren verwendung |
-
1982
- 1982-01-26 CA CA000394904A patent/CA1209477A/en not_active Expired
- 1982-01-27 AU AU79865/82A patent/AU549784B2/en not_active Expired
- 1982-01-28 GB GB8202414A patent/GB2095551B/en not_active Expired
- 1982-01-29 ZA ZA82605A patent/ZA82605B/xx unknown
- 1982-02-01 ES ES509234A patent/ES8302455A1/es not_active Expired
- 1982-02-02 NZ NZ199632A patent/NZ199632A/en unknown
- 1982-02-02 SE SE8200591A patent/SE453153B/sv not_active IP Right Cessation
- 1982-02-03 GR GR67200A patent/GR78386B/el unknown
- 1982-02-03 IL IL64924A patent/IL64924A/xx unknown
- 1982-02-04 DK DK048382A patent/DK157976C/da active
- 1982-02-22 JP JP57026172A patent/JPS57159708A/ja active Granted
- 1982-03-09 AT AT0092982A patent/AT395533B/de not_active IP Right Cessation
- 1982-03-09 DE DE1993175106 patent/DE19375106I2/de active Active
- 1982-03-09 DE DE19823208505 patent/DE3208505A1/de active Granted
- 1982-03-12 FR FR8204196A patent/FR2502624B1/fr not_active Expired
- 1982-03-18 PL PL1982235509A patent/PL130564B1/pl unknown
- 1982-03-18 BE BE0/207599A patent/BE892541A/fr not_active IP Right Cessation
- 1982-03-19 IT IT48034/82A patent/IT1147916B/it active
- 1982-03-24 LU LU84031A patent/LU84031A1/de unknown
- 1982-03-25 NL NL8201251A patent/NL192664C/nl not_active IP Right Cessation
- 1982-03-25 IE IE703/82A patent/IE52936B1/en unknown
- 1982-03-25 HU HU82914A patent/HU186489B/hu unknown
- 1982-03-25 CH CH1857/82A patent/CH652306A5/de not_active IP Right Cessation
-
1989
- 1989-05-11 HK HK391/89A patent/HK39189A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0207544A1 (en) | Multi-compartment syringe | |
| CA2619255A1 (en) | Twin-chamber receptacle without a bypass | |
| US4477452A (en) | Composition of matter comprising a lyophilized preparation of a penicillin derivative | |
| BG61752B1 (bg) | Аерозолни състави под налягане | |
| US3914419A (en) | Two compartment one unit consecutively injectable liquid vitamin package | |
| TWI885001B (zh) | 欣得泰乾粉注射劑穩定劑型 | |
| DE60038118T2 (de) | Formulierungen von wachstumshormonen | |
| SE453153B (sv) | Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin | |
| DE60215129T3 (de) | Esmolol-enthaltende zubereitungen | |
| Miller et al. | A comparative evaluation of compounding costs and contamination rates of intravenous admixture systems | |
| US4534977A (en) | Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin | |
| WO2006073505A2 (en) | Container closure delivery system | |
| CA1269205A (en) | Adsorption-resistant peptide composition | |
| US20150216928A1 (en) | Daptomycin injectable formulation | |
| Allen Jr et al. | Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids | |
| Wermeling et al. | Osmolality of small-volume intravenous admixtures | |
| EP0095751B1 (en) | Secretin composition and method for preventing the adsorption of secretin | |
| Cooper et al. | Plastic containers for pharmaceuticals: testing and control | |
| SE463804B (sv) | En anvaendningsklar farmaceutisk komposition av vinkadimerasalter | |
| GB2029700A (en) | Etomidate-containing compositions | |
| CN120835787A (zh) | 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法 | |
| WO2018163201A1 (en) | A device, method and kit for the reconstitution of a solid or semi solid pharmaceutical composition | |
| EP0180303B1 (en) | Parenteral composition | |
| CA2236690A1 (en) | Aqueous acyclovir formulation and method for storing same | |
| Alexander et al. | Particulate contamination in solutions of antibiotics packed as dry powders in vials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8200591-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8200591-9 Format of ref document f/p: F |